LZTR1: A Promising Adaptor of the CUL3 Family

Overview

Journal Oncol Lett

Specialty Oncology

Date 2021 Jun 11

PMID 34113392

Citations 9

Authors

Hui Zhang

Xinyi Cao

Jian Wang

Qian Li

Yiting Zhao

Xiaofeng Jin

Affiliations

Soon will be listed here.

Abstract

The study of the disorders of ubiquitin-mediated proteasomal degradation may unravel the molecular basis of human diseases, such as cancer (prostate cancer, lung cancer and liver cancer, etc.) and nervous system disease (Parkinson's disease, Alzheimer's disease and Huntington's disease, etc.) and help in the design of new therapeutic methods. Leucine zipper-like transcription regulator 1 (LZTR1) is an important substrate recognition subunit of cullin-RING E3 ligase that plays an important role in the regulation of cellular functions. Mutations in LZTR1 and dysregulation of associated downstream signaling pathways contribute to the pathogenesis of Noonan syndrome (NS), glioblastoma and chronic myeloid leukemia. Understanding the molecular mechanism of the normal function of LZTR1 is thus critical for its eventual therapeutic targeting. In the present review, the structure and function of LZTR1 are described. Moreover, recent advances in the current knowledge of the functions of LZTR1 in NS, glioblastoma (GBM), chronic myeloid leukemia (CML) and schwannomatosis and the influence of LZTR1 mutations are also discussed, providing insight into how LZTR1 may be targeted for therapeutic purposes.

Citing Articles

Frontal lobe intra-axial schwannoma harboring a CHD7::VGLL3 fusion and heterozygous TSC2 p.F1510del mutation in a young child.

Nguyen A, Berger B, Abdullaev Z, Gearhart S, Castro-Echeverry E, Aldape K Mol Biol Rep. 2025; 52(1):112.

PMID: 39792305 PMC: 11723850. DOI: 10.1007/s11033-024-10201-8.

Phenotypic Expansion of Autosomal Dominant -Related Disorders with Special Emphasis on Adult-Onset Features.

Uliana V, Ambrosini E, Taiani A, Cesarini S, Cannizzaro I, Negrotti A Genes (Basel). 2024; 15(7.

PMID: 39062695 PMC: 11276570. DOI: 10.3390/genes15070916.

Low protein expression of LZTR1 in hepatocellular carcinoma triggers tumorigenesis activating the RAS/RAF/MEK/ERK signaling.

Ye G, Wang J, Xia J, Zhu C, Gu C, Li X Heliyon. 2024; 10(12):e32855.

PMID: 38994114 PMC: 11237970. DOI: 10.1016/j.heliyon.2024.e32855.

Machine learning and multi-omics data reveal driver gene-based molecular subtypes in hepatocellular carcinoma for precision treatment.

Wang M, Yan X, Dong Y, Li X, Gao B PLoS Comput Biol. 2024; 20(5):e1012113.

PMID: 38728362 PMC: 11230636. DOI: 10.1371/journal.pcbi.1012113.

Effect of ubiquitin protease system on DNA damage response in prostate cancer (Review).

Lin Y, Jin X Exp Ther Med. 2023; 27(1):33.

PMID: 38125344 PMC: 10731405. DOI: 10.3892/etm.2023.12321.

References

Cornelius R, Yang C, Ellison D . Hypertension-causing cullin 3 mutations disrupt COP9 signalosome binding. Am J Physiol Renal Physiol. 2019; 318(1):F204-F208. PMC: 6985821. DOI: 10.1152/ajprenal.00497.2019. View

Song Z, Liu T, Chen J, Ge C, Zhao F, Zhu M . HIF-1α-induced RIT1 promotes liver cancer growth and metastasis and its deficiency increases sensitivity to sorafenib. Cancer Lett. 2019; 460:96-107. DOI: 10.1016/j.canlet.2019.06.016. View

Motta M, Fidan M, Bellacchio E, Pantaleoni F, Schneider-Heieck K, Coppola S . Dominant Noonan syndrome-causing LZTR1 mutations specifically affect the Kelch domain substrate-recognition surface and enhance RAS-MAPK signaling. Hum Mol Genet. 2018; 28(6):1007-1022. DOI: 10.1093/hmg/ddy412. View

Merker V, Esparza S, Smith M, Stemmer-Rachamimov A, Plotkin S . Clinical features of schwannomatosis: a retrospective analysis of 87 patients. Oncologist. 2012; 17(10):1317-22. PMC: 3481897. DOI: 10.1634/theoncologist.2012-0162. View

Smith M, Pathmanaban O, Coope D, King A, Evans D . Comment on: SMARCB1 Gene Mutation Predisposes to Earlier Development of Glioblastoma: A Case Report of Familial GBM. J Neuropathol Exp Neurol. 2021; 80(3):289-290. DOI: 10.1093/jnen/nlaa105. View

Schubbert S, Zenker M, Rowe S, Boll S, Klein C, Bollag G . Germline KRAS mutations cause Noonan syndrome. Nat Genet. 2006; 38(3):331-6. DOI: 10.1038/ng1748. View

Bigenzahn J, Collu G, Kartnig F, Pieraks M, Vladimer G, Heinz L . LZTR1 is a regulator of RAS ubiquitination and signaling. Science. 2018; 362(6419):1171-1177. PMC: 6794158. DOI: 10.1126/science.aap8210. View

Heng L, Kennedy J, Smithson S, Newbury-Ecob R, Churchill A . New macular findings in individuals with biallelic KLHL7 gene mutation. BMJ Open Ophthalmol. 2019; 4(1):e000234. PMC: 6440596. DOI: 10.1136/bmjophth-2018-000234. View

Evans D, Bowers N, Tobi S, Hartley C, Wallace A, King A . Schwannomatosis: a genetic and epidemiological study. J Neurol Neurosurg Psychiatry. 2018; 89(11):1215-1219. DOI: 10.1136/jnnp-2018-318538. View

10.

Crisa E, Nicolosi M, Ferri V, Favini C, Gaidano G, Patriarca A . Atypical Chronic Myeloid Leukemia: Where Are We Now?. Int J Mol Sci. 2020; 21(18). PMC: 7555965. DOI: 10.3390/ijms21186862. View

11.

Cirstea I, Kutsche K, Dvorsky R, Gremer L, Carta C, Horn D . A restricted spectrum of NRAS mutations causes Noonan syndrome. Nat Genet. 2009; 42(1):27-9. PMC: 3118669. DOI: 10.1038/ng.497. View

12.

Adams J, KELSO R, Cooley L . The kelch repeat superfamily of proteins: propellers of cell function. Trends Cell Biol. 1999; 10(1):17-24. DOI: 10.1016/s0962-8924(99)01673-6. View

13.

Song Y, Xu Y, Pan C, Yan L, Wang Z, Zhu X . The emerging role of SPOP protein in tumorigenesis and cancer therapy. Mol Cancer. 2020; 19(1):2. PMC: 6942384. DOI: 10.1186/s12943-019-1124-x. View

14.

Enchev R, Schulman B, Peter M . Protein neddylation: beyond cullin-RING ligases. Nat Rev Mol Cell Biol. 2014; 16(1):30-44. PMC: 5131867. DOI: 10.1038/nrm3919. View

15.

Yamamoto G, Aguena M, Gos M, Hung C, Pilch J, Fahiminiya S . Rare variants in SOS2 and LZTR1 are associated with Noonan syndrome. J Med Genet. 2015; 52(6):413-21. DOI: 10.1136/jmedgenet-2015-103018. View

16.

Madden S, Itzhaki L . Structural and mechanistic insights into the Keap1-Nrf2 system as a route to drug discovery. Biochim Biophys Acta Proteins Proteom. 2020; 1868(7):140405. DOI: 10.1016/j.bbapap.2020.140405. View

17.

Goulding R, Chenoweth M, Cuyun Carter G, Boye M, Sheffield K, John W . KRAS mutation as a prognostic factor and predictive factor in advanced/metastatic non-small cell lung cancer: A systematic literature review and meta-analysis. Cancer Treat Res Commun. 2020; 24:100200. DOI: 10.1016/j.ctarc.2020.100200. View

18.

Aoki Y, Niihori T, Inoue S, Matsubara Y . Recent advances in RASopathies. J Hum Genet. 2015; 61(1):33-9. DOI: 10.1038/jhg.2015.114. View

19.

Garcia-Horton A, Lipton J . Treatment Outcomes in Chronic Myeloid Leukemia: Does One Size Fit All?. J Natl Compr Canc Netw. 2020; 18(10):1421-1428. DOI: 10.6004/jnccn.2020.7627. View

20.

Rape M . Ubiquitylation at the crossroads of development and disease. Nat Rev Mol Cell Biol. 2017; 19(1):59-70. DOI: 10.1038/nrm.2017.83. View